Abstract Immunotherapy with Bacillus Calmette-Guérin (BCG)-an attenuated strain of Mycobacterium bovis (M. bovis) used for anti tuberculosis immunization-is a clinically established procedure for the treatment of superficial bladder cancer. However, the mode of action has not yet been fully elucidated, despite much extensive biological experience. The purpose of this paper is to develop a first mathematical model that describes tumor-immune interactions in the bladder as a result of BCG therapy. A mathematical analysis of the ODE model identifies multiple equilibrium points, their stability properties, and bifurcation points. Intriguing regimes of bistability are identified in which treatment has potential to result in a tumor-free equilibrium or a full-blown tumor depending only on initial conditions. Attention is given to estimating parameters and validating the model using published data taken from in vitro, mouse and human studies. The model makes clear that intensity of immunotherapy must be kept in limited bounds. While small treatment levels may fail to clear the tumor, a treatment that is too large can lead to an over-stimulated immune system having dangerous side effects for the patient.
Introduction
Bladder cancer is a growth of malignant cells initiating in the urinary bladder. The most common neoplasm of the bladder, transitional cell carcinoma (TCC), originates from the transitional epithelium that lines the bladder cavity. It first grows superficially on the inner surface of the bladder as in-situ cancer, expanding from the original site into the adjacent areas. Upon further progression, it invades the bladder wall and vessels, spreading into the neighboring organs as well as systemically forming distant metastases. The treatment of the disease is dependent upon the stage at diagnosis. In the invasive stages, the bladder cancer can only be treated with an aggressive surgery, radiation, and/or chemotherapy (Lamm et al., 2005) . However, during the superficial phase the tumor is amenable to local excision, where small regions of cancerous tissue are surgically resected by direct inspection through the urethra, in a procedure called transurethral resection (TUR) (SchenkBraat and Bangma, 2005) . To complete the procedure in the superficial stage, an adjuvant treatment administered into the cavity is generally recommended to destroy any malignant cells that remain following the resection. The two complementary approaches to adjuvant treatment of superficial bladder cancer are the intravesical chemotherapy and the intravesical application of bacillus Calmette-Guérin (BCG) (immunotherapy). Although both adjuvant approaches are practiced clinically, it is generally held that immunotherapy is slightly more effective, is associated with less side effects (Nseyo and Lamm, 1997) , and is currently the most frequently applied treatment (Chopin and Gattegno, 2002) .
Here we mathematically study the adjuvant immunotherapy of superficial bladder cancer based on the introduction of Bacillus Calmette-Guérin-an attenuated strain of Mycobacterium bovis (M. bovis)-used originally for the treatment of tuberculosis. Bevers et al. (2004) provide a detailed review of the treatment. See also Alexandroff et al. (1999) for a general assessment. Briefly: BCG is introduced into the bladder where it adheres to the damaged regions of the bladder wall. There it primarily infects tumor cells, and to a significantly lesser extent normal cells, and locally stimulates the patient's immune response. This elicits a predominantly confined immune reaction, which mainly targets BCG infected tumor cells and may potentially eliminate the remaining tumor. Thus, the malignant cells are attacked by the patient's own immune system rather than through external chemical or surgical intervention.
BCG is effective in 50-70% of patients (efficacy is defined as disappearance of pathology/symptoms/clinical signs for 5-10 years) with significant reduction in 10 years mortality. However, for a disappointingly high fraction of in-situ patients, the tumor will still recur within this period (Andius and Holmang, 2004) . Currently there are no reliable prognostic factors for accurately predicting treatment success (Kim and Steinberg, 2001 ). The various protocols differ mainly in the frequency of the administration and the dose of the introduced bacillus. The most common protocol is based upon treatment suggested by Morales et al. (1976) and involves weekly instillations of BCG over a 6-week period. Extension of BCG treatment (maintenance immunotherapy) is sometimes used to increase efficacy. BCG treatment side effects include high fever, general malaise and chills, and more rarely persistent bladder infection, BCG induced lung infection, liver toxicity, and BCG sepsis (Kim and Steinberg, 2001 ). The severe side-effects occur in less then 10% of patients.
It is postulated that the outcome of BCG therapy for the treatment of superficial bladder cancer depends on a complex interaction between the tumor population, the BCG and the immune system (Bevers et al., 2004) as set out in Fig. 1 . We believe that these interactions may be better understood by a mathematical model that elucidates the contribution of the various factors in the therapeutic process. The mathematical analysis may illuminate the dominant factors that control the process and that might be externally controlled to improve the outcome. Here we study these interactions by a system of four nonlinear ordinary differential equations that describes the tumor and the immune dynamics for the case of a continued application of BCG therapy. We show that the model exhibits a nontrivial equilibrium structure. Noteworthy, a stable tumor-free equilibrium exists within a biologically feasible parameter regime, and we show the necessary BCG treatment parameters that correspond to tumor eradication. Moreover, we identify regimes of bistability in which a "diseased" tumor laden equilibrium coexists with a "cured" tumor-free equilibrium and where the actual outcome is dependent upon initial conditions (see also Kirschner and Panetta, 1998) . The presence of bistability has obvious practical implications for immunotherapy treatment. In addition we discuss more general therapeutic implications.
Mathematical model

Biological framework
The cascade of events leading to BCG-associated tumor cell clearance may be summarized as follows (see Fig. 1 ):
• The initial immune response to BCG. After its instillation in the bladder, BCG (B in Fig. 1 ) accumulates near the bladder wall, and in superficial tumor cells. In binding to the cell wall, BCG is internalized and processed by both antigen-presenting cells (APC) and uninfected tumor cells denoted by T u via endocytosis. The "BCG-infected" tumor cells are referred to as T i .
• The antitumor effects: the effector cells. BCG antigens stimulate a strong immune response characterized by a massive appearance of cytokines in the infected areas and in the urine. The cytokine cascade stemming from the APC activates cytotoxic T cells, lymphocyte-activated killer (Schenk-Braat and Bangma, 2005) , natural killer cells (Bohle and Brandau, 2003) and such, which ultimately cause injury to the BCGinfected tumor cells (Patard et al., 1998) . For simplicity, we referred to all cells belonging to these different arms of the immune systems as effector cells (E). This targeting of infected tumor cells can lead to elimination of the entire tumor.
Formulation of model equations
We describe the interaction between tumor cells within the bladder, the immune system, and the BCG immunotherapy with a system of nonlinear ODEs. Our modeling approach has similarities to the studies of Kuznetsov et al. (1994) , Kirschner and Panetta (1998 ), De Pillis et al. (2005 , 2006 although these authors do not deal with bladder cancer. In our model the tumor cells are divided into two subpopulations; those that have been infected (T i ) with BCG (B) and those that are still uninfected (T u ) and susceptible. As the tumor cells are divided into two pools, the total number of tumor cells is given by:
Since effector cells (E) target and destroy infected tumor cells (T i ) the latter must decrease at an intensity that is proportional to their encounter. By taking random mixing as a first approximation, the encounter rate is proportional to the product p 3 ET i , where p 3 is a rate constant. Similarly, tumor cells become infected with BCG at a rate proportional to the product p 2 BT u where p 2 is a rate coefficient. Thus the dynamics of the individual pools of tumor populations are:
In the above equations, the number of uninfected tumor cells increase due to the natural growth rate G(T u ) (specified below) of the tumor. Infected tumor cells, on the other hand, contribute little to tumor growth, because BCG has an anti-proliferative effect against human urothelial carcinoma cell lines (Bevers et al., 2004; Bevers, personal communication; Chen et al., 2005) . Typically, BCG is introduced into the bladder cavity by once a week instillations or pulses over a 6-week period. Such processes introduce time dependent discontinuities into the model. The resulting nonautonomous structure can be of considerable analytical complexity, but in some cases can be studied by the method of impulses (Lakshmikantham et al., 1989) . At the present stage, we have chosen to simplify the problem by assuming that BCG is introduced into the bladder at a constant rate b, although in a follow up paper we will explore the effects of pulsed therapy. The free BCG binds to malignant urothelial tumor cells, infecting them at a rate p 2 (De Boer et al., 1996; Durek et al., 1999) . BCG is lost at the rate p 1 by interaction with macrophages and dendritic cells, and natural killer cells (Wigginton and Kirschner, 2001) . To help simplify the model we collectively group the immune cells (APC, natural killer cells, lymphocyte-activated killer) into the single term, effector cells (E). This yields the following equation:
The term (−μ 1 ) is effective net growth rate of BCG and may be viewed as:
−μ 1 = proliferation rate-mortality rate.
For BCG in the bladder, the proliferation rate is negligible (Brandau, private communication); BCG is very slowly growing even in culture. As such, μ 1 reasonably approximates the BCG mortality or decay rate. The activation of the immune system, which relates to recruitment and maturation of T -killer cells, BCG-activated killers (BAK) are, represented by the following effector cells dynamics:
Here p 4 EB is the immune response activation that results from the encounter between immune cells and BCG, and controlled by the parameter p 4 . Infected tumor cells stimulate recruitment of cytotoxic effector cells from the bone marrow (Bevers et al., 2004 ) at a rate given by αT i . The rate of inactivation of E cells via encounter with T i is given by p 5 ET i , and μ 2 is the natural mortality rate of effector cells. We arrive at the following system of ordinary differential equations:
The tumor growth rates
In this study we compare two functional forms for the per-capita growth rate of the tumor
(a) The logistic model, in which the tumor growth is given by:
where r is the growth rate of tumor cells, and β is the death of tumor cells as a result of self-limiting competition for resources such as oxygen and glucose. β −1 may be viewed as the maximum carrying capacity of the tumor under logistic growth. (b) The exponential model with tumor growth:
with r a constant. This describes an exponentially increasing tumor mass. Note that the exponential model is a special case of the logistic model for which β = 0.
The well known Gompertz law (Banks, 1994) is also a potentially useful functional growth rate form. However, given the latter's similarities to the logistic equation, it is unlikely to make qualitative differences to the main results found here.
Scaling of parameters
The system (2) and (3a), (3b) may be placed in dimensionless form, using the following scaling:
The parameters p 1 , and p 2 may be eliminated by choosing the additional scaling:
In practice, there is a trade off between reducing parameters and retaining parameters that have operational meaning. For these reasons we choose the scaling |B 0 | = |E 0 | = |T i 0 | = |T u 0 | = 10 6 cells (similar to Kuznetsov et al., 1994) , which ensures that the model is in dimensionless form, but retains most of the original parameters. Dropping the prime notation for convenience, we obtain the final form of the model equations here specified with logistic tumor growth:
where all parameters are positive. Again, the exponential growth model is retrieved by setting β = 0.
Model parameters
To complete the mathematical model it is useful to estimate parameter ranges that are realistic and agree with values reported in the literature. Although this plays some role in the analysis that follows, we emphasise that our goal here is not to derive a predictive simulation model using exact rate parameters. Instead, we aim to find generic qualitative results that are intrinsic to the model's structure. As our analytical results are not tied to any specific growth rates, we do not require precise rate values. This notwithstanding, parameter values are compiled from peer-reviewed mathematical models of cancer growth and immunotherapy, and in many cases we have attempted to improve these estimates. A summary of the parameter values used in this paper is given in Table 1 . In this section we briefly discuss the acquisition of the parameters of the unscaled model (2) i.e., before nondimensionalization.
The natural mortality rate of BCG μ 1 was estimated from experimental data given in the study of Archuleta et al. (2002) . Figure 2a shows the mortality rate of the Mycobacterium avium (M. avium) strain, similar to M. bovis (both are slow growing). The BCG decay rate is exponential (linear on a logarithmic scale) over the first τ = 10 days and estimated as μ 1 = ln 10 7 2×10 5 = 0.16 cells/day in that period. The decay then decelerated and was calculated as μ 1 = 0.07 over the first 23 days. Over a 50 day period, the decay was μ 1 = 0.04. For the model, a rough average of these values seemed a reasonable first estimate for the decay rate and we thus set μ 1 = 0.1 in our simulations, corresponding to half life for M. avium of 7 days (τ 0.5 = ln 2/μ 1 = 7).
Typical values for the BCG instillation b were obtained from the clinical data of Cheng et al. (2004) in which patients received weekly BCG doses corresponding to 2.2 × 10 8 -6.4 × 10 8 c.f.u.'s (colony-forming units, i.e., number of viable bacterial cells). Most of this leaves the bladder within the first two hours of instillation. Brandau (personal communication) estimates that 99% of the BCG is lost this way. A reasonable daily rate for b is thus in the range 0.01 × (2.2 × 10 8 -6.4 × 10 8 )/7 days = 3 × 10 5 -10 × 10 5 c.f.u./day. Many studies report estimates of the parameters r and β (3a), (3b) describing the tumor's logistic or exponential growth (see summary in Table 1 ). Kuznetsov et al. (1994) used an estimate of r = 0.18 days −1 and De Pillis et al. (2005) used r = 0.51 days −1 , for the growth rate r which translate to very fast doubling times of approximately 1-4 days. The data of Aranha et al. (2000) in Fig. 2b is compatible with bladder cancer in vitro growth rates of r ∼ 0.37-0.5 days −1 with a doubling time of approximately 1.5-2 days. We suspect that these large growth rates may be biased as they represent cell growth in vitro in favorable medium without the constrains that normally exist in the tissue. On the other hand, the in vivo studies in the medical literature report growth rates of r that equal 0.001-0.03 days −1 for breast cancer (Spratt et al., 1993; Shochat et al., 1999) . Here we assume that the in vivo rates of bladder cancer growth are an order of magnitude slower than in vitro and approximate r to be in the range r = 0.01-0.045 days −1 for our simulations.
Under logistic growth, the parameter β is estimated by noting that the maximum carrying capacity of the tumor is T u = β −1 cells. Lämmle et al. (2002) give information regarding the sizes of bladder cancer, as determined by MR imaging. They report tumor sizes ranging from 2-32 mm in radius. From this, we calculated the maximal tumor surface area assuming it being circular in shape. It was also assumed that the tumor is some 3 cells deep allowing the volume to be determined based on the length of cell being approximately 10 µm. Given that 1 mm 3 ∼ 10 6 cells (Spratt et al., 1993) , the number of tumor cells is:
−2 × 10 6 = 0.9 × 10 8 cells, Fig. 9 which explores large changes in growth rate r and thus β = 0.11 × 10 −7 . Where possible, our estimates of the parameters in the immunological response (μ 2 , p 1 , p 3 , p 5 , α) are based on the works of Kuznetsov et al. (1994) , Kirschner and Panetta (1998) and Wigginton and Kirschner (2001) , although some of the variables used there are rough estimates. The parameter p 2 was estimated by imposing reasonable time scales to the process of tumor eradication (several weeks) in simulations. Due to the highly non-trivial nature of the multidimensional parameter estimation and its nonuniqueness (Press et al., 1992) , some of the values chosen here should be viewed as at least reasonable order-of-magnitude indicators. Table 1 lists each parameter, its baseline value, and source. Note that dimensionless estimates are obtained from source values using transformations given in Section 2.4.
Model analysis
Invariance of positive orthant
Assume that the model begins with positive initial conditions:
The following elementary considerations show that trajectories of model equations (4) must then remain in the positive orthant (R 4 + ) for all time, i.e. the region is invariant. This is based on the following observations. From (4), if b > 0 then when B = 0, dB/dt = b > 0 and it follows that B(t) > 0 for all t (given that B (0) 
We use this property in the section that follows.
Equilibrium and stability analysis
The equilibria of the model (4) are found by setting all derivatives to zero and solving for B * , E * , T * i and T * u , with the star notation indicating the variables are at their equilibrium values. Equations (4) have multiple equilibria but, given the invariance of the positive orthant, we need only focus on the nonnegative equilibria assuming all initial conditions are positive.
When analyzing the stability of each equilibrium of the above nonlinear system, one examines the Jacobian:
Let the eigenvalues of the Jacobian examined at a particular equilibrium be λ = [λ 1 , λ 2 , λ 3 , λ 4 ] and set
If Λ < 0, then all eigenvalues must have negative real parts and the equilibrium is locally stable.
The following sections provide a stability analysis of the model's nonnegative equilibria, first in the absence of immunotherapy (Section 3.3) and second under conditions of continuous therapy (Section 3.4).
Absence of BCG treatment (b = 0)
The model (4) in the absence of therapy (b = 0) is characterized by two different types of equilibria that are summarized in Table 2 . Table 2 Summary of the stability characteristics for the nonnegative equilibria solutions of system (4) in the absence of therapy (b = 0). The tumor-free equilibrium E 1 is common to both exponential (E) and logistic (L) growth models whereas the tumor-equilibrium E 2 exists only for the logistic model. The exponential model lacks any stable equilibrium
Tumor equilibrium-Liapunov stable
The tumor-free equilibrium
which exists in both the logistic and exponential models.
Stability:
The eigenvalues of the Jacobian (5) evaluated at equilibrium are: λ = [−1, −μ, 0, r] for both models. Since Λ = max i {Re(λ i )} = r > 0, one eigenvalue is always positive and the tumor free equilibrium is an unstable saddle point for all parameters. The eigenvector of the Jacobian corresponding to the eigenvalue λ = r is easily found to be e = [0, 0, 0, 1]. This refers to a state dominated by the tumor's exponential growth: dT u /dt = rT u or T u (t) = T u (0) exp(rt).
The tumor equilibrium (logistic model)
The logistic model (β > 0) exhibits a second nonnegative equilibrium that corresponds to a state where the tumor reaches its full scale carrying capacity
. (This equilibrium does not exist in the exponential model (β = 0).) At the equilibrium, effector cells are absent (E * = 0) because there is no infection to stimulate the immune system. With the immune system "switched off" there is no resistance to tumor growth.
Stability:
The eigenvalues of the Jacobian at this equilibrium are:
The zero eigenvalue in (6) indicates that the equilibrium is characterized by neutral stability. However, numerical simulations indicate that the equilibrium is locally stable (see Fig. 3 ). This is a case where the linearized dynamics fail to represent the true dynamics of the nonlinear system due to the presence of a zero eigenvalue. Nevertheless, it is possible to show that the equilibrium is in fact Liapunov stable for initial conditions in R 4 + (see Appendix A).
Continuous BCG immunotherapy (b > 0)
The constant BCG immunotherapy is a treatment program that introduces a continuous antigenic stimulus. With constant BCG immunotherapy treatment (b > 0) both the logistic and exponential models have three distinct types of equilibria, are summarized in Table 3 , denoted here as the "tumor-free" equilibrium E Table 1 , with β = 5 (for demonstration); r = 0.12; b = 0.
Table 3
Summary of the stability conditions for the nonnegative equilibria solutions of system (4) under immunotherapy (b > 0). The tumor-free equilibria E b 1 and E b 2 are identical for both exponential (E) and logistic (L) growth models. The parameter ranges for which the equilibria are stable are given in right-hand column Apart from λ 3 = 0, all eigenvalues are negative if:
The zero eigenvalue indicates that the system will be neutrally stable in this parameter range, yet simulations indicate local stability. As the numerical simulations in Fig. 4 show, the tumor rapidly disappears if the BCG influx rate b satisfies the criteria given in (7). Although we are unable to provide a rigorous stability analysis of this equilibrium (b > 0), it is possible to sketch the principle processes that give rise to local stability despite the zero eigenvalue. A linear analysis of (4) in a neighborhood of this equilibrium shows that for B → B * = b and T u → T * u = 0 as t → ∞. Equation (4) can now be simplified to almost the same reduced system (6) which was found to be Liapunov stable. Table 1 , with: β = 0.0155; r = 0.12; b = 1.9. Note that in the present scaling each time unit is equivalent to 10 days. Faster tumor eradication may be obtained by increasing the tumor infection rate p 2 . For example, p 2 = 2.3 corresponds to large scale tumor eradication within 1-2 weeks.
The criterion given in (7) gives the ranges for which constant BCG treatment is able to clear the tumor to a point where the immune system response is no longer required (E * = 0). An intuitive understanding of the breakpoints of this range may be gained as follows. The left-hand side breakpoint (in (7)) corresponds to the point where r = bp 2 . At equilibrium, the term bp 2 is the per-capita infection rate of the tumor. Thus we see that when this infection rate is greater (although not too much greater) than the tumor growth rate r, the tumor-free equilibrium is stable. For smaller infection rates, the tumor's growth rate dominates and the tumor-free equilibrium destabilizes. The right hand breakpoint occurs when μ = bp 4 , which at equilibrium, is the per-capita rate of stimulation of the effector cells by bacteria. When this stimulation rate is less than the effector cells own mortality rate μ, the tumor-free equilibrium is stable. Should it be larger, effector cells are over-stimulated and the equilibrium loses stability.
It is of interest to identify those factors, which stabilize the desired tumor-free equilibrium state:
1. The rate of BCG treatment (b) is relatively large compared to the tumor growth rate (r). 2. The BCG infection rate of the tumor (p 2 ) is relatively large and the treatment is effective by "brute force". 3. The immune system activation (p 4 ) is not strong enough to provoke a side-effect reaction (E * > 0, see below).
It is noteworthy that the tumor dynamics linearized about the equilibrium may be approximated as dTu dt = (−p 2 b + r)T u . The solution of the equation is:
which decreases exponentially to zero when the equilibrium is stable [(−p 2 b + r) < 0]. This shows that with the application of immunotherapy, the tumor will retreat at a rate that can be controlled by the intensity of treatment b.
"Side effect" equilibrium E b 2 (logistic and exponential) E b
The equilibrium is characterized by a permanent over-stimulated immune system. Before BCG therapy only low numbers of leukocytes can be detected in the bladder. After repeated BCG instillation, the influx of different types of effector cells (macrophages, lymphocytes) that aim to kill cells infected with BCG is observed (Bohle and Brandau, 2003) . Often this transient behavior subsides with time (de Reijke et al., 1999) . Occasionally however, BCG may invoke a widespread immune response. This in turn may cause troubling systemic side effects: high fever, malaise and rarely an immune related lung inflammation (Elkabani et al., 2000) . These side effects are considered features to be associated with equilibrium E b 2 and may be permanent.
Stability:
The eigenvalues of the Jacobian matrix are:
Manipulation of the expressions for the eigenvalues shows that the equilibrium is nonnegative and locally stable with all eigenvalues having negative real parts if:
where the right hand side inequality (
is simply an appearance of the condition that E * > 0. Interestingly, (7) shows that in the regime in which E b 2 is stable (9), the tumor free equilibrium E b 1 is unstable and vice-versa. Thus there is a transcritical bifurcation at the point b = μ p 4 which separates the regimes of stability between the two equilibria. From (7) and (9) it is evident that E b 1 and E b 2 will be stable when the tumor growth rate (r) is sufficiently smaller than r crit = μp 2 /p 4 .
Tumor equilibrium E b
(logistic and exponential)
This equilibrium is characterized by all populations having positive equilibrium values:
where
and T * u is a real positive root of a fifth-order polynomial. (a) Equilibrium E b 3 for logistic growth rate (β > 0): Simple precise stability criteria for equilibrium E b 3 are not obtainable analytically. However, numerical studies (e.g., see region III in Fig. 9a ) indicate that a sufficient (but not necessary) condition for the equilibrium to be stable is that both the tumor-free and the "side-effect" equilibria (E 
, 2 stabilizes and is the only stable equilibrium. In this regime, although the tumor is eradicated, the treatment level is so strong that the immune system remains active, and E * increases with b (Lamm et al., 2005) . Note that under more intense treatment levels (b > r/p 2 ), E b 3 exists, but is not stable.
Figures 6 and 7, show that the logistic version of the model has the same qualitative features. There are, however, noteworthy differences. At low levels of immunotherapy the model attains a stable equilibrium where the tumor reaches a fixed finite size rather Table 1 with β = 0; r = 0.028. 2 (both tumorfree). In this regime, the equilibrium that is eventually reached depends solely on the initial conditions. In the range 1.5 < b < 7, tumors whose size are above the critical line shown in Fig. 6 will be attracted to the tumor equilibrium while tumors below this line will be attracted to the tumor-free equilibrium. This means that the outcome of the immunotherapy can depend critically on the given state of the tumor. If the tumor is eradicated at relatively high levels of immunotherapy (b > μ/p 4 = 3.4), this corresponds to the side-effect equilibrium E b 2 . Interestingly, for large tumor growth rates r > r crit , the tumor-equilibrium E b 3 is extremely robust and is stable independent of the amount of immunotherapy b. With r = 1.1, for example, Fig. 9b plots the tumor equilibrium until b = 45 although the same trend is found for enormous doses of therapy beyond b = 1,000. That is, no amount of immunotherapy can eradicate the model-tumor in this regime. In order to help elucidate this feature, for the given parameter ranges, it is possible to approximate E b 3 with good accuracy as: This reveals that B * and T * u are indeed independent of the intensity of immunotherapy b, while E * increases linearly. In this regime, the infected tumor cells T * i are found to be relatively small in number (T * i ∼ 0.8). The processes promoting this behavior may be understood as follows. The high levels of therapy do not enhance net BCG equilibrium concentration. Instead the BCG flux turns-over rapidly and is mostly taken up and shunted through to the effector cell population boosting the equilibrium E * . The large number of effector cells reduces the infected tumor cells to small numbers. However, since the available BCG (B * ) is also relatively small and does not increase with therapy b, infection of the tumor cells T u is slowed down. As a result the high growth rate of the tumor cells T u dominates and the tumor cannot be eradicated.
Discussion
We present here a new, relatively simple, mathematical model of BCG immunotherapy in superficial bladder cancer. The model exhibits multiple steady states, which depend on biologically related parameters and initial conditions. A clinically relevant feature of the model is the nontrivial dependence of the dynamics on the treatment rate b. Specifically, three distinct dynamical pattern can be distinguished, explicitly dependent upon the appropriate mode of tumor growth. (8)). 3. For high treatment rates b > μ/p 4 , the tumor mass will be eliminated, with permanent side effects that persist as long as BCG treatment is applied. This results in the so-called "side-effect" tumor-free equilibrium E b 2 which is characterized by an overdriven immune response.
In the case of logistic growth rate, bistability is often observed and any outcome will also depend on the initial conditions (as discussed below).
We will next discuss some possible limitations of the present study and the feasible future solutions to them. Finally, we will apply our results, to briefly discuss some possible causes for BCG treatment failure.
In our work, the complex biological processes of tumor, immune system, and BCG interactions are captured by a 4-dimensional system. Additional variables that would provide a more detailed description of the biology may obviously be envisioned. For example, Kirschner and Panetta (1998) have chosen to study the explicit effects of the immune cytokine interleukin-2 (IL-2) of the dynamics of the effector cells. In our model this effect is considered indirectly via the interaction terms such as p 4 EB and αT i . A more detailed characterization of the immune response may be explicitly considered by expansion of the model. Such is the case, for example, if we wish to analyze the possible favorable effect of augmenting BCG immunotherapy interferon-alpha2B (INF-α 2B ) (Kassouf and Kamat, 2004) .
A trade off between the analytical tractability and the reliability of the representation of the underlying biological system should always be taken into account. The need for additional complexity should ultimately be determined by experimental results that would either verify or contradict the model predictions. For example, the clinical fact that the spontaneous cure of TCC is very rarely observed (Papac, 1996) is accounted for in our model in that we do not allow for direct effect of the effectors cells on the uninfected tumor cells. Thus, with no or little treatment (low treatment rate b < r/p 2 ) the model will predict that no cure is possible. If on the other hand some immune response may be evoked even towards uninfected cells, this may change the dynamics. A clinical scenario in which additional antigenicity will be conveyed to the tumor by transgenic methods is currently being considered (Dumey et al., 2005) . Such a trade off can also be invoked when concerning our approximation of BCG treatment at constant rate b. An analysis of a nonautonomous version of the model where pulses of treatment are explicitly accounted for is currently under way.
In this model, if continuous treatment is stopped and the (uninfected) cancer is not entirely removed from the bladder the tumor will always return to its untreated equilibrium. However, if there are no further uninfected cancer cells and treatment is stopped, the model will remain at the tumor-free equilibrium state, even though unstable. It will persist in this condition until the next cancer cell appears and the tumor will recur again. We speculate that the pulsed treatment scheme might offer a means to stabilize the tumor-free state.
The dynamical system studied here is space independent while the actual dynamics of tumor growth may have spatial dependency. For example, the actual bladder cancer initially spreads superficially upon the surface of the bladder, and is only several cells deep. This may indicate that the effect of the invasive properties and the nutrient-limited processes may need to be considered and studied, for example, with partial differential equations (such as in Franks et al., 2003) . Moreover, as the invasion front is only on the periphery of the disk, the geometry of the tumor rim may affect the dynamics (see, for example, Bru et al., 2004) . These considerations can be a scope for future models.
Finally, BCG is currently the most effective therapy in the prophylaxis of superficial TCC of the urinary bladder following primary resection (TUR). Yet, a significant fraction of patients fail the treatment (Nseyo and Lamm, 1997) . In view that both the dose rate b and the tumor growth rate r are critical bifurcation parameters (Figs. 5, 6, 7 , and 9), we wish to suggest that in many cases treatment failure stems from insufficient application of the dose rate b that does not match the appropriate value of r. The model predicts that there are cases where immunotherapy cannot help. In particular, Fig. 9b shows that high tumor growth rates can prevent immunotherapy from eradicating the tumor, no matter how strong the therapy might be. Noteworthy, our model suggests that if a feasible way of administrating continuous dose rate b can be devised, this will in many cases enable effective treatment. A specific suggestion about clinical feasibility of such an approach should be a theme of further studies and is beyond the scope of the current paper.
Moreover, due to the interesting feature of bistability, the outcome of BCG treatment is dependent on the initial conditions of tumor following surgical curettage. Thus, while some tumors may potentially respond to BCG treatment, the initial tumor burden may sit in the domain of attraction of the unfavorable steady state and ultimately result in treatment failure (Fig. 8) . That initial conditions can further steer the treatment to either failure or success may be the key to the observation that addition of intra-vesical chemotherapy prior to BCG treatment may be beneficial in some cases (Kaasinen et al., 2000) .
Indeed an ultimate, but albeit still distant, application for the model is to aid in defining the appropriate rate of BCG instillation in a particular clinical situation. To enable such a potential application for individual bladder cancer patients, certain clinical parameters need to be measured prospectively:
• Repeated direct assessment of the tumor. The determination of the tumor area following TUR curettage will provide initial conditions for model input. Subsequent examinations will provide with the response to treatment. Though frequent observations by cystoscopy is hardly a feasible clinical option, alternative noninvasive monitoring of tumor status (for example, by radioactive imaging Chiou et al., 1999) could be considered.
• Calculation of the tumor properties. The growth rate can be obtained indirectly by assessment of bromodeoxyuridine (BrdU) incorporation or antigen Ki67 expression (Limas et al., 1993) . Related features such the proliferation an invasive potential can be accessed by micro-array analysis (Modlich et al., 2004 ).
• Measurement of the actual BCG concentration in the bladder. Although the vast majority of the bacteria are cleared within several hours following instillation, some evidence exists that BCG persist in the bladder for much longer periods (Bowyer et al., 1995) . This may alter the actual treatment rate b, which may be significant near the bifurcation points (see also the clinical implications section).
• Measurement of the rate of infection of the tumor cells with BCG and the rate of interaction of BCG with APC (see Durek et al., 1999 for elegant experiments).
• Measurement of the in vivo intra-bladder immune response. Here, the kinetics of urine cytokines may be considered as valuable surrogates (de Reijke et al., 1999) .
Such dedicated experimental setting is beyond the ability of most practice oriented clinical institutions. However, given the prospect of potential cure in otherwise devastating disease, as may be hinted by our analysis, a search for an intense dialog with theoretically inclined clinicians is appropriate. 
